Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Pioglitazone in Non-diabetic NASH
NCT05605158Phase 3Unknown
- Sponsor
- Tanta University
- Start
- Nov 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of empagliflozin in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Tanta University. Primary endpoints: Change in fibrosis index based on the 4 factors at 24 weeks, Change in aspartate transaminase-to-platelet ratio index at 24 weeks and 1 more. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05605158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605158.